Sanofi India Q3 Review - Divestment Of Nutraceuticals Complete: ICICI Securities

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..ICICI Securities Report.Sanofi India Ltd.’s Q3 CY21’s performance was below estimates, however, adjusting for the divestment of nutraceutical division, it was broadly in line.Revenue grew 9.9% YoY to Rs 7.5 billion (our estimate: Rs 8.1 billion).Ebitda margin dropped 170 basis points YoY and 500 bps QoQ to 26.3% (our estimate: 28.5%). Adjusted profit after tax grew 15.0% to Rs 1.5 billion. Sanofi India recorded an exceptional income of Rs 4.9 billion from the sale of nutraceutical division. In the past few years, the company’s growth and profitability were fuelled by the power brands. We remain positive on the company considering high visibility of strong growth from its chronic therapy exposure in domestic formulations, strong balance sheet with deep cash reserves, and strong brand equity built over the years..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Sanofi India Q3 Review - Divestment Of Nutraceuticals Complete: ICICI Securities

Sanofi India Q3 Review - Divestment Of Nutraceuticals Complete: ICICI Securities

Choose a plan